Company / Current Liabilities
NOVAVAX INC Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$459.9M
FY2025
5-year range
$459.9M / $2.5B
FY2021-FY2025
Trend
-60.2%
vs FY2024
Sector context
#36 of 213
Health Care
What the data says
NOVAVAX INC's current liabilities of $460M is higher than 83% of companies in the Health Care sector (FY2025). Current Liabilities has declined for 3 consecutive years, from $2.5B in FY2022 to $460M in FY2025.
Based on SEC 10-K filings.
$460M in FY2025 with a 5-year CAGR of -4.5%. Top quartile in the Health Care sector.
Improved from $1.6B to $460M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -42.8%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Sector benchmark
-71.0% below sector average
Key checks
Key Insights
- NOVAVAX INC's current liabilities has declined for 3 consecutive years.
- 5-year CAGR of -4.5%, indicating a declining trend.
- In FY2025, current liabilities decreased 60.2% year-over-year.
- Ranks #36 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $459.9M | -60.2% |
| FY2024 | $1.2B | -29.4% |
| FY2023 | $1.6B | -33.5% |
| FY2022 | $2.5B | +2.9% |
| FY2021 | $2.4B | +312.4% |
| FY2020 | $579.7M | +2147.2% |
| FY2019 | $25.8M | -43.4% |
| FY2018 | $45.5M | -38.2% |
| FY2017 | $73.7M | +10.9% |
| FY2016 | $66.4M | -13.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026